Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Abstract

Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at valine–82, although insufficient to confer resistance, appeared first in most patients. Significant phenotypic resistance required multiple mutations in HIV protease, which emerged subsequently in an ordered, stepwise fashion. The appearance of resistance mutations was delayed in patients with higher plasma levels of ritonavir. Early mutants retained susceptibility to structurally diverse protease inhibitors, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Richman, D.D. Zidovudine resistance of human immunodeficiency virus. Rev. Infect. Dis. 12, S507–S512 (1990).

    Article  Google Scholar 

  2. Kempf, D. et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92, 2484–2488 (1995).

    Article  CAS  Google Scholar 

  3. Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528–1533 (1995).

    Article  CAS  Google Scholar 

  4. Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534–1539 (1995).

    Article  CAS  Google Scholar 

  5. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995).

    Article  CAS  Google Scholar 

  6. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995).

    Article  CAS  Google Scholar 

  7. Cameron, B. et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28–Feb. 1, 1996, Abstract LB6a.

    Google Scholar 

  8. Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569–571 (1995).

    Article  CAS  Google Scholar 

  9. Pachl, C. et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 8, 446–454 (1995).

    Article  CAS  Google Scholar 

  10. Myers, G., Wain-Hobson, S., Korber, B., Smith, R.F. & Pavlakis, G.N. Human Retroviruses and AIDS (Los Alamos National Laboratory, Los Alamos, New Mexico, 1993).

    Google Scholar 

  11. Markowitz, M. et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69, 701 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Jacobsen, H. et al. In-vivo resistance to HIV proteinase inhibitor saquinavir—an update. AIDS Res. Hum. Retrovir. 11, S169–S169 (1995).

    Google Scholar 

  13. Pauwels, R. et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309–321 (1988).

    Article  CAS  Google Scholar 

  14. Partaledis, J.A. et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethy-lamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69, 5228–5235 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Patick, A.K. et al. Antiviral and resistance studies of AG 1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40, 292–297 (1996).

    Article  CAS  Google Scholar 

  16. Schapiro, J.M. et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. (in the press).

  17. Heath-Chiozzi, M. et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28–Feb. 1, 1996, Abstract LB6b.

    Google Scholar 

  18. Gulick, R. et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28–Feb. 1, 1996, Abstract LB7.

    Google Scholar 

  19. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582–1586 (1996).

    Article  CAS  Google Scholar 

  20. Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483–489 (1995).

    Article  CAS  Google Scholar 

  21. Ho, D.D. et al. Characterization of HIV-1 variants with increased resistance to a C 2 symmetric protease inhibitor. J. Virol. 68, 2016–2020 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Gulnik, S.V. et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282–9287 (1995).

    Article  CAS  Google Scholar 

  23. Jacobsen, H. et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206, 527–534 (1995).

    Article  CAS  Google Scholar 

  24. Kitchen, V.S. et al. Safety and activity of saquinavir in HIV infection. Lancet 345, 952–955 (1995).

    Article  CAS  Google Scholar 

  25. Japour, A.J., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37, 1095–1101 (1993).

    Article  CAS  Google Scholar 

  26. Maschera, B., Furfine, E. & Blair, E.D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69 5431–5436 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molla, A., Korneyeva, M., Gao, Q. et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2, 760–766 (1996). https://doi.org/10.1038/nm0796-760

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0796-760

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing